Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia

IntroductionOlder patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. DNA methyltransferases (DNMTs) and histone-deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets. However, their effect...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Qingyang Liu, Jingjing Yang, Lei Lv, Xiawei Zhang, Meng Li, Lingmin Xu, Sai Huang, Yu Jing, Liping Dou
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2025-02-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	venetoclax azacitidine CACAG-VEN regimen older patients acute myeloid leukemia
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1525110/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!